Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity

Myxofibrosarcoma and myxoid liposarcomas are relatively common soft tissue tumours that are characterized by their so‐called myxoid extracellular matrix and have to some extent overlap in histology. The exact composition and potential role of their myxoid extracellular matrix are insufficiently understood. To gain more insight into the biomolecular content of these tumours, we have studied 40 well‐documented myxofibrosarcoma and myxoid liposarcoma cases using imaging mass spectrometry. This technique provides a multiplex biomolecular imaging analysis of the tissue, spanning multiple molecular domains and without a priori knowledge of the tissue's biomolecular content. We have developed experimental protocols for analysing the peptide, protein, and lipid content of myxofibrosarcoma and myxoid liposarcomas, and have detected proteins and lipids that are tumour‐type and tumour‐grade specific. In particular, lipid changes observed in myxoid liposarcomas could be related to pathways known to be affected during tumour progression. Unsupervised clustering of the biomolecular signatures was able to classify myxofibrosarcoma and myxoid liposarcomas according to tumour type and tumour grade. Closer examination of histologically similar regions in the tissues revealed intratumour heterogeneity, which was a consistent feature in each of the myxofibrosarcomas studied. In intermediate‐grade myxofibrosarcoma, it was found that single tissue sections could contain regions with biomolecular profiles similar to high‐grade and low‐grade tumours, and that these regions were associated with the tumour's nodular structure, thus supporting a concept of tumour progression through clonal selection. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Stefan M Willems,et al.  Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option , 2010, Molecular Cancer.

[2]  L. McDonnell,et al.  Peptide and protein imaging mass spectrometry in cancer research. , 2010, Journal of proteomics.

[3]  Richard M Caprioli,et al.  Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. , 2010, Journal of proteome research.

[4]  M. Clench,et al.  Novel molecular tumour classification using MALDI–mass spectrometry imaging of tissue micro-array , 2010, Analytical and bioanalytical chemistry.

[5]  H. Shim,et al.  Molecular proteomics imaging of tumor interfaces by mass spectrometry. , 2010, Journal of proteome research.

[6]  M. Gönen,et al.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.

[7]  L. Guillou,et al.  Soft tissue sarcomas with complex genomic profiles , 2010, Virchows Archiv.

[8]  Lisa H Cazares,et al.  Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.

[9]  M. Wiweger,et al.  Running GAGs: myxoid matrix in tumor pathology revisited , 2009, Virchows Archiv.

[10]  R. Sciot,et al.  Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix , 2009, Journal of cellular and molecular medicine.

[11]  Richard M Caprioli,et al.  Molecular imaging of proteins in tissues by mass spectrometry , 2008, Proceedings of the National Academy of Sciences.

[12]  Sören-Oliver Deininger,et al.  MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. , 2008, Journal of proteome research.

[13]  J. Lloreta,et al.  Genomic Imbalances in Urothelial Cancer: Intratumor Heterogeneity Versus Multifocality , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[14]  Pierre P Massion,et al.  High‐throughput proteomic analysis of formalin‐fixed paraffin‐embedded tissue microarrays using MALDI imaging mass spectrometry , 2008, Proteomics.

[15]  P. A. Pérez-Mancera,et al.  FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPARγ and C/EBPα and Activating eIF4E , 2008, PloS one.

[16]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[17]  André M Deelder,et al.  Mass spectrometry image correlation: quantifying colocalization. , 2008, Journal of proteome research.

[18]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[19]  B. Delahunt,et al.  Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra‐glandular spread of the initial neoplastic clone , 2008, The Journal of pathology.

[20]  Sei Ueda,et al.  中咽頭 myxofibrosarcoma 例 , 2008 .

[21]  P. Hogendoorn,et al.  Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition , 2008, Histopathology.

[22]  Michelle L. Reyzer,et al.  MALDI imaging mass spectrometry: molecular snapshots of biochemical systems , 2007, Nature Methods.

[23]  P. A. Pérez-Mancera,et al.  Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. , 2007, Carcinogenesis.

[24]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[25]  Gerhard Jakse,et al.  Identifying prostate carcinoma by MALDI-Imaging. , 2007, International journal of molecular medicine.

[26]  L. Pantanowitz,et al.  Myxoid liposarcoma , 2007, Diagnostic cytopathology.

[27]  P. Chaurand,et al.  Processing MALDI Mass Spectra to Improve Mass Spectral Direct Tissue Analysis. , 2007, International journal of mass spectrometry.

[28]  C. Maley,et al.  Cancer as an evolutionary and ecological process , 2006, Nature Reviews Cancer.

[29]  Richard M. Caprioli,et al.  Molecular Assessment of the Tumor Protein Microenvironment Using Imaging Mass Spectrometry , 2006 .

[30]  Nicolò Riggi,et al.  Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. , 2006, Cancer research.

[31]  P. Åman,et al.  The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. , 2006, The American journal of pathology.

[32]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[33]  M. Debiec‐Rychter,et al.  Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model , 2006, Modern Pathology.

[34]  Patrik Edén,et al.  Intratumor versus intertumor heterogeneity in gene expression profiles of soft‐tissue sarcomas , 2005, Genes, chromosomes & cancer.

[35]  A. Ståhlberg,et al.  Myxoid liposarcoma FUS‐DDIT3 fusion oncogene induces C/EBP β‐mediated interleukin 6 expression , 2005, International journal of cancer.

[36]  Roy A Jensen,et al.  Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. , 2004, The American journal of pathology.

[37]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[38]  R. Sciot,et al.  A phase II trial with rosiglitazone in liposarcoma patients , 2003, British Journal of Cancer.

[39]  Michelle L. Reyzer,et al.  Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. , 2003, Journal of mass spectrometry : JMS.

[40]  D. Cory,et al.  Biochemical correlates of thiazolidinedione‐induced adipocyte differentiation by high‐resolution magic angle spinning NMR spectroscopy , 2002, Magnetic resonance in medicine.

[41]  R. Solé,et al.  Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Itoh,et al.  Involvement of the Pro-oncoprotein TLS (Translocated in Liposarcoma) in Nuclear Factor-κB p65-mediated Transcription as a Coactivator* , 2001, The Journal of Biological Chemistry.

[43]  G. Fleuren,et al.  Allelotype analysis of flow‐sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases , 2000, Genes, chromosomes & cancer.

[44]  C. Fletcher,et al.  Myxoid tumours of soft tissue , 1999, Histopathology.

[45]  D. Cory,et al.  Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy , 1999, Magnetic resonance in medicine.

[46]  Kerry Souza,et al.  Correlation of lipid content and composition with liposarcoma histology and grade , 1997, Annals of Surgical Oncology.

[47]  M. A. Smith,et al.  Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. , 1996, The American journal of surgical pathology.

[48]  N. Konishi,et al.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.

[49]  F. Mitelman,et al.  Cytogenetic intratumor heterogeneity in soft tissue tumors. , 1994, Cancer genetics and cytogenetics.

[50]  H. Zinszner,et al.  A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. , 1994, Genes & development.

[51]  N. Mandahl,et al.  Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma , 1993, Nature.

[52]  M. Karas,et al.  Matrix-assisted ultraviolet laser desorption of non-volatile compounds , 1987 .

[53]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[54]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[55]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[56]  T. Mentzel Biological continuum of benign, atypical, and malignant mesenchymal neoplasms - does it exist? , 2000, The Journal of pathology.

[57]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Cornelisse,et al.  Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. , 1991, Cytometry.